Status
Conditions
About
This non-interventional study (NIS) was a retrospective chart review analyzing existing data from patients participating in the asciminib MAP.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Study Population: Key Inclusion/Exclusion Criteria Inclusion criteria
Diagnosis of CML (chronic phase, accelerated phase or blast crisis).
Confirmed presence of T315I mutation prior to asciminib initiation.
Patients enrolled in the asciminib MAP and received their first dose of asciminib between 01 November 2018 and 30 April 2022. Patients must have received at least one dose of asciminib.
Appropriate approval was obtained for the patient chart review including:
Exclusion criteria
• Age less than 18 years old at the time of initiating asciminib treatment.
31 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal